SEC Filing Summary: Ra Medical Systems, Inc. (RMED)
Business Context and Reporting Period
This Form 8-K was filed on December 9, 2019, reporting events occurring on December 3, 2019. The registrant is Ra Medical Systems, Inc., a Delaware corporation trading on the New York Stock Exchange under the symbol RMED. The filing addresses executive compensation adjustments and changes to director compensation structures.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial figure disclosed is a specific cash retention bonus of $179,220 awarded to the Interim CEO and CFO.
Material Changes and Events
- Executive Retention Bonus: The Compensation Committee approved a $179,220 cash retention bonus for Andrew Jackson (Interim CEO and CFO). Payments are structured in four equal installments due on December 15, 2019, March 31, 2020, June 30, 2020, and September 30, 2020, contingent on continued service.
- Director Compensation Shift: Chairman Martin Colombatto and directors William Enquist, Richard Mejia, Jr., and Mark Saad elected to receive their 2020 annual retainer compensation in stock options rather than cash.
- Option Grant Details: Director options are scheduled for automatic grant on January 5, 2020. The number of options is calculated by dividing the expected cash retainer by the option value, with a vesting schedule of 25% per quarter.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. The primary contingency noted is that unpaid portions of the executive retention bonus become payable if Mr. Jackson is terminated without "cause" or resigns for "good reason," provided he executes a release of claims.
Investor Verification Checklist
- Verify the total number of stock options to be granted to directors on January 5, 2020, based on the option valuation used.
- Confirm the impact of the $179,220 bonus on the company's immediate cash flow and Q4 2019 expenses.
- Review the definitions of "cause" and "good reason" in the company's standard severance agreements to assess the likelihood of accelerated bonus payments.
- Check subsequent filings for the actual grant date and vesting schedule confirmation for the director options.